|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,805.00 GBX | -1.15% |
|
+0.78% | +34.05% |
| Dec. 05 | Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns | RE |
| Dec. 05 | Health Rounds: Shingles vaccine reduces risk of death from dementia, study finds | RE |
Business description: GSK plc
Number of employees: 68,629
Sales by Activity: GSK plc
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Commercial Operations | - | - | 29.32B | 30.33B | 31.38B |
Corporate and Other Unallocated Turnover | 28M | - | - | - | - |
Consumer Healthcare | 10.03B | 9.61B | - | - | - |
Vaccines | 6.98B | 6.78B | - | - | - |
Pharmaceuticals | 17.06B | 17.73B | - | - | - |
Geographical breakdown of sales: GSK plc
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
United States (US) | 14.56B | 15.09B | 14.54B | 15.82B | 16.38B |
International | 18.56B | 18.05B | 14.09B | 13.82B | 14.28B |
United Kingdom (UK) | 980M | 975M | 695M | 693M | 708M |
Executive Committee: GSK plc
| Manager | Title | Age | Since |
|---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 56 | 2017-03-31 |
Julie Brown
DFI | Director of Finance/CFO | 63 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Chief Tech/Sci/R&D Officer | - | 2021-11-30 | |
Tony Wood
CTO | Chief Tech/Sci/R&D Officer | - | 2022-01-18 |
Composition of the Board of Directors: GSK plc
| Director | Title | Age | Since |
|---|---|---|---|
Emma Walmsley
BRD | Director/Board Member | 56 | 2016-12-31 |
Hal Barron
BRD | Director/Board Member | 63 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
Charles Bancroft
BRD | Director/Board Member | 65 | 2020-04-30 |
Anne Beal
BRD | Director/Board Member | 62 | 2021-05-05 |
Harry Dietz
BRD | Director/Board Member | 67 | 2021-12-31 |
Vishal Sikka
BRD | Director/Board Member | 58 | 2022-07-17 |
| Director/Board Member | 67 | 2022-08-31 | |
Julie Brown
BRD | Director/Board Member | 63 | 2023-04-30 |
Wendy Becker
BRD | Director/Board Member | 60 | 2023-09-30 |
Holdings: GSK plc
| Name | Equities | % | Valuation |
|---|---|---|---|
| 127,054,524 | 75% | 3,779,982,626 $ | |
WAVE LIFE SCIENCES LTD. 10.54% | 16,775,691 | 10.54% | 151,652,247 $ |
CUREVAC N.V. 7.37% | 16,591,937 | 7.37% | 88,600,944 $ |
VIR BIOTECHNOLOGY, INC. 6.16% | 8,550,954 | 6.16% | 50,963,686 $ |
| 421,983 | 6.46% | 31,980,691 $ | |
LYELL IMMUNOPHARMA, INC. 7.13% | 1,512,659 | 7.13% | 25,200,899 $ |
DONG-A ST CO., LTD. 7.87% | 736,456 | 7.87% | 25,154,678 $ |
BIOVERSYS AG 4.34% | 253,472 | 4.34% | 7,643,813 $ |
Company details: GSK plc
Group companies: GSK plc
| Name | Category and Sector |
|---|---|
GlaxoSmithKline IHC Ltd.
 GlaxoSmithKline IHC Ltd. Provides banking services | |
GlaxoSmithKline Ltd.
 GlaxoSmithKline Ltd. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline Ltd. is a company based in Hong Kong, Hong Kong. |
Pharmaceuticals: Major
|
GlaxoSmithKline Ltd.
GlaxoSmithKline Ltd. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline Ltd. is a company based in Hong Kong, Hong Kong. |
Pharmaceuticals: Major
|
Corixa Corp.
 Corixa Corp. BiotechnologyHealth Technology Develops and manufactures oncology and immunology products |
Biotechnology
|
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Develops and manufactures oncology and immunology products |
Biotechnology
|
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.15% | +0.78% | +34.30% | +20.95% | 96.56B | |
| -0.41% | -6.06% | +22.21% | +171.61% | 905B | |
| -0.27% | -2.41% | +35.24% | +13.98% | 487B | |
| -1.15% | -0.71% | +28.32% | +36.69% | 400B | |
| +0.26% | +1.14% | +20.97% | +3.22% | 330B | |
| +0.58% | -2.73% | +27.58% | +20.73% | 281B | |
| +0.19% | +2.49% | +19.23% | +24.83% | 255B | |
| -1.16% | -4.87% | -3.27% | -9.42% | 248B | |
| +1.24% | -2.33% | -60.59% | -30.34% | 214B | |
| -3.02% | -4.51% | +21.03% | +15.44% | 178B | |
| Average | -0.49% | -1.92% | +14.50% | +26.77% | 339.31B | |
| Weighted average by Cap. | -0.39% | -2.69% | +18.09% | +54.77% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GSK Stock
- Company GSK plc
Select your edition
All financial news and data tailored to specific country editions
